Zevra Therapeutics
ZVRA
71 hedge funds and large institutions have $73.1M invested in Zevra Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 12 closing their positions.
195% more call options, than puts
Call options by funds: $19.9M | Put options by funds: $6.77M
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
1% more funds holding
Funds holding: 70 → 71 (+1)
0.39% less ownership
Funds ownership: 22.66% → 22.27% (-0.39%)
26% less capital invested
Capital invested by funds: $98.4M → $73.1M (-$25.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.87M |
| 2 |
Goldman Sachs
New York
|
+$1.7M |
| 3 |
Renaissance Technologies
New York
|
+$1.67M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.44M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$9.27M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.13M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.32M |
| 4 |
VF
Virtu Financial
New York
|
-$916K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$345K |
ZVRA Hedge Fund Activity: Q3 2021 in Review
71 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2021, worth a combined $73.1M — down 26% from $98.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ZVRA positions and 12 closed out — a net gain of 2 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.87M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $9.27M sold.
- 71 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2021, up from 70 in Q2 2021.
- Funds reported $73.1M of Zevra Therapeutics stock for Q3 2021, down 26% quarter-over-quarter.
- 14 funds opened new Zevra Therapeutics positions in Q3 2021 and 12 closed out, a net change of +2 holders.
- The largest Zevra Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $3.87M added.
- The largest Zevra Therapeutics seller in Q3 2021 was Hudson Bay Capital Management, an estimated $9.27M sold.
Based on aggregated 13F filings for Q3 2021.